AI Summary
Danaher reported a solid Q2 with revenue at $6.3B and net earnings of $870M ($1.23 per share), up 60% YoY, along with an 8% rise in non-GAAP EPS to $1.94. Core revenue rose 3.0% (4.5% excluding respiratory testing), and operating cash flow was $1.5B. The Masimo acquisition has closed earlier than expected, enabling a higher full-year EPS target of $8.45–$8.60, while the company also updates guidance for 3Q and full-year core sales growth. A new non-GAAP metric, core sales excluding respiratory testing, was introduced to better reflect underlying growth, and tariff refunds will be excluded from core starting in Q3 2026.
Sentiment Rationale
Solid Q2 beat, EPS uplift, and Masimo closing imply near-term upside to the stock; the new core metric and tariff-exclusion guidance reduce noise around volatile respiratory testing, supporting a higher multiple. Historical analogs show Danaher stock reacting positively to earnings beats and successful acquisitions that meaningfully raise mid-term earnings trajectory.
Trading Thesis
Bullish on DHR in the next 3–6 months as Masimo-driven EPS accretion and guidance uplift reset investor expectations.
Market-Moving
- Masimo acquisition completion supports higher 2026 adjusted EPS and full-year guidance.
- New 'core sales excluding respiratory testing' metric may alter multiple and valuation.
- Pending StatLab acquisition could add mid-single-digit core growth and EPS accretion in 2027.
Key Facts
- Q2 2026 earnings: net $870M, $1.23 per diluted share, up 60% YoY.
- Revenue $6.3B, up 5.5% YoY; Non-GAAP core revenue +3.0% (ex respiratory +4.5%).
- Masimo acquisition completed; Danaher lifts 2026 non-GAAP EPS guidance to $8.45–$8.60.
- Outlook: 3Q core revenue +2.0% to 3.0%; full year core +3% to 4%.
- New metric: Core sales excluding respiratory testing; tariff refunds to be excluded from core starting Q3 2026.
Companies Mentioned
- Masimo Corporation (MASI): Acquisition completed earlier; anticipated earnings synergies support higher 2026 guidance.
- StatLab (SLMP) Acquisition (SLMP): Pending Leica/Danaher deal; closing targeted by end-2026; StatLab revenue ~$250M in 2025; accretive in first full year of ownership.
- Danaher Corporation (DHR): Posted strong Q2 results; raising 2026 guidance; near-term catalysts include Masimo close and StatLab deal.
Earnings
Category: Earnings. The release centers on quarterly results, updated full-year guidance, and ongoing M&A activity (Masimo closed; StatLab pending). The shift to non-GAAP disclosures and the new Core sales excluding respiratory testing metric reflect a focus on underlying growth versus volatile respiratory demand, aiding valuation under a growth-with-accretive-acquisition narrative.